Impact of Preexisting Cognitive Impairment and Race/Ethnicity on Functional Outcomes Following Intracerebral Hemorrhage

In intracerebral hemorrhage (ICH), preexisting cognitive impairment has been identified as a risk factor for increased mortality and morbidity. However, previous studies examined predominantly White populations; therefore, the prevalence and effect of preICH cognitive impairment has not been studied...

Full description

Saved in:
Bibliographic Details
Published in:Stroke (1970) 2021-02, Vol.52 (2), p.603-610
Main Authors: Sawyer, Russell P., Yim, Eunji, Coleman, Elisheva, Demel, Stacie L., Sekar, Padmini, Woo, Daniel
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Black or African American
Black People
Cerebral Hemorrhage - complications
Cerebral Hemorrhage - mortality
Cognitive Dysfunction - complications
Cohort Studies
Ethnicity
Female
Hispanic or Latino
Hospitalization
Humans
Male
Middle Aged
Prevalence
Propensity Score
Prospective Studies
Racial Groups
Risk Factors
Treatment Outcome
White People
Withholding Treatment - statistics & numerical data
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In intracerebral hemorrhage (ICH), preexisting cognitive impairment has been identified as a risk factor for increased mortality and morbidity. However, previous studies examined predominantly White populations; therefore, the prevalence and effect of preICH cognitive impairment has not been studied in a multiethnic cohort. This limits the generalizability of previous findings. We sought to investigate the role of preexisting cognitive impairment in a multiethnic population on short-term mortality and functional outcomes after ICH. Patients with ICH were prospectively enrolled as cases for the GERFHS III (Genetic and Environmental Risk Factors for Hemorrhagic Stroke) Study and the Ethnic/Racial Variations of ICH (ERICH) Study. Cognitive impairment before ICH was defined as positive history of dementia or treatment with donepezil, galantamine, memantine, or rivastigmine on chart abstraction or baseline interview. Specific outcomes-modified Rankin Scale score at 3 months (0-2 versus ≥3), Barthel Index score (
ISSN:0039-2499
1524-4628
DOI:10.1161/STROKEAHA.120.030084